Paola Imbrici
Overview
Explore the profile of Paola Imbrici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Della Vecchia S, Imbrici P, Liantonio A, Naef V, Damiani D, Licitra R, et al.
Biomed Pharmacother
. 2025 Jan;
183:117800.
PMID: 39753095
Lafora disease (LD) is an ultra-rare and still incurable neurodegenerative condition. Although several therapeutic strategies are being explored, including gene therapy, there are currently no treatments that can alleviate the...
2.
Mele M, Mautone F, Ragnatela I, DAlessandro D, Rossi L, Granatiero M, et al.
Heart Lung
. 2025 Jan;
70:230-235.
PMID: 39752808
Background: It is crucial to distinguish type-1 myocardial infarction (T1MI) from type-2 myocardial infarction (T2MI) at admission and during hospitalization to avoid unnecessary invasive exams and inappropriate admissions to the...
3.
Conte E, Boccanegra B, Dinoi G, Pusch M, De Luca A, Liantonio A, et al.
Biomolecules
. 2024 Sep;
14(9).
PMID: 39334956
Tuberous sclerosis complex (TSC) is a rare multisystem disorder caused by heterozygous loss-of-function pathogenic variants in the tumour suppressor genes TSC1 and TSC2 encoding the tuberin and hamartin proteins, respectively....
4.
Imbrici P, De Bellis M, Liantonio A, De Luca A
Methods Mol Biol
. 2024 Sep;
2834:333-349.
PMID: 39312173
Rapid and detailed post-marketing surveillance of drugs and vaccine is required to enable assessment of their real-world safety and effectiveness. Spontaneous reporting from healthcare professionals and citizens is recognized as...
5.
Dinoi G, Conte E, Palumbo O, Benvenuto M, Coppola M, Palumbo P, et al.
Biomedicines
. 2024 Aug;
12(8).
PMID: 39200163
Loss-, gain-of-function and mixed variants in (Nav1.1 voltage-gated sodium channel) have been associated with a spectrum of neurologic disorders with different severity and drug-responsiveness. Most variants are heterozygous changes occurring...
6.
Mele M, Ragnatela I, Romano M, Tabella E, Rossi L, Mautone F, et al.
Am J Cardiol
. 2024 Aug;
230:41-46.
PMID: 39187227
Frailty status is linked with a poorer clinical outcome, and patients with frailty are often less revascularized, even with percutaneous coronary intervention (PCI). We therefore sought to assess the impact...
7.
Telesca M, De Angelis A, Donniacuo M, Bellocchio G, Riemma M, Mele E, et al.
Eur J Pharmacol
. 2024 Jul;
978:176794.
PMID: 38968980
Heart failure (HF) remains a huge medical burden worldwide, with aging representing a major risk factor. Here, we report the effects of sacubitril/valsartan, an approved drug for HF with reduced...
8.
Conte E, Mantuano P, Boccanegra B, Imbrici P, Dinoi G, Lenti R, et al.
Front Pharmacol
. 2024 Jul;
15:1393746.
PMID: 38962308
During aging, sarcopenia and decline in physiological processes lead to partial loss of muscle strength, atrophy, and increased fatigability. Muscle changes may be related to a reduced intake of essential...
9.
Mele M, Mele A, Imbrici P, Samarelli F, Purgatorio R, Dinoi G, et al.
Molecules
. 2024 Jun;
29(11).
PMID: 38893525
Oral anticoagulant therapy (OAT) for managing atrial fibrillation (AF) encompasses vitamin K antagonists (VKAs, such as warfarin), which was the mainstay of anticoagulation therapy before 2010, and direct-acting oral anticoagulants...
10.
Cerchiara A, Imbrici P, Quarta R, Cristiano E, Boccanegra B, Caputo E, et al.
Ann N Y Acad Sci
. 2024 Mar;
1534(1):130-144.
PMID: 38517756
Myogenesis is essential for skeletal muscle formation, growth, and regeneration and can be altered in Duchenne muscular dystrophy (DMD), an X-linked disorder due to the absence of the cytoskeletal protein...